|
Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our study identifies a common variant rs1056515 as a genetic marker for CAD and rare variants in LD with rs1056515 leading to decreased expression of RGS5, which contributes to atherosclerosis by impairing endothelial cell function.
|
31605122 |
2019 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast, depression-like behavior was worsened in RGS5-deficient mice treated with angiotensin II.
|
31625976 |
2019 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast, depression-like behavior was worsened in RGS5-deficient mice treated with angiotensin II.
|
31625976 |
2019 |
|
Hyperparathyroidism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Parathyroid-Targeted Overexpression of Regulator of G-Protein Signaling 5 (RGS5) Causes Hyperparathyroidism in Transgenic Mice.
|
30690792 |
2019 |
|
Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we show that the inflammatory genes Ccl11 and Rgs5 are involved in RMS growth.
|
30650360 |
2019 |
|
Benign Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These primarily benign tumors grow in a perivascular fashion and diffusely express canonical pericyte markers such as CD146, smooth muscle actin (SMA), platelet-derived growth factor receptor beta (PDGFR-β), and RGS5.
|
31147874 |
2019 |
|
Hyperparathyroidism, Primary
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results provide evidence that RGS5 can modulate signaling from CASR and support a role for RGS5 in the pathogenesis of PHPT through inhibition of CASR signaling.
|
30690792 |
2019 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In contrast, depression-like behavior was worsened in RGS5-deficient mice treated with angiotensin II.
|
31625976 |
2019 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of RGS5 in EOC was negatively associated with peritoneal metastasis (P=0.004), but it was not found to be associated with age, tumor size, clinical stage or lymph node metastasis (P>0.05).
|
30365142 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of RGS5 in EOC was negatively associated with peritoneal metastasis (P=0.004), but it was not found to be associated with age, tumor size, clinical stage or lymph node metastasis (P>0.05).
|
30365142 |
2019 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our data indicated that RGS5 is crucial for the occurrence and development of ovarian cancer, and that RGS5 and its signaling pathway may serve as anti‑angiogenesis targets for the treatment of ovarian cancer.
|
30365142 |
2019 |
|
Vascular inflammations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Through siRNA knockdown and adenoviral overexpression, we further showed that RGS5 regulated endothelial inflammation, vascular remodeling, as well as canonical NF-κB signaling activation.
|
31605122 |
2019 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Rare genetic variants in linkage disequilibrium with rs1056515 were identified in CAD patients leading to a decreased expression of RGS5.
|
31605122 |
2019 |
|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, our data strongly indicate that RGS5 is a novel modulator of pathological progression after MI that functions NF-κB and MAPK signalling.
|
29534968 |
2018 |
|
Post MI
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our results showed that the loss of RGS5 decreased the post-MI survival rate and left ventricular (LV) function and increased the infarct size.
|
29534968 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma.
|
29434872 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Genetic variants of the RGS5 gene are believed to be risk factors for hypertension and cardiovascular diseases.
|
26782409 |
2015 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of RGS5 resulted in significantly lower adhesion and migration abilities of the lung cancer cells (P<0.01).
|
25891540 |
2015 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of RGS5 resulted in significantly lower adhesion and migration abilities of the lung cancer cells (P<0.01).
|
25891540 |
2015 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of RGS5 resulted in significantly lower adhesion and migration abilities of the lung cancer cells (P<0.01).
|
25891540 |
2015 |
|
Adult Liver Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further analysis showed that the over-expression of RGS5 is associated with liver cancer recurrence, venous infiltration, and patients' poor survival.
|
23868206 |
2013 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further analysis showed that the over-expression of RGS5 is associated with liver cancer recurrence, venous infiltration, and patients' poor survival.
|
23868206 |
2013 |
|
Malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further analysis showed that the over-expression of RGS5 is associated with liver cancer recurrence, venous infiltration, and patients' poor survival.
|
23868206 |
2013 |
|
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These results indicate that over-expression of RGS5 promotes tumor metastasis by inducing epithelial-mesenchymal transition in HCC.
|
23868206 |
2013 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To toughen the relevance of the findings, we demonstrate RGS5 in the blood vessels of other cancer models endowed with a proangiogenic environment, such as human melanoma and renal carcinoma xenografts; to the contrary, it was undetectable in the vasculature of normal mouse tissues.
|
22130514 |
2012 |